A new alliance between MakroCare and LSK Global Pharmaceutical Services offers a single entry point to a range of drug development and commercialisation services in key Asian markets as well as the US.
MakroCare’s home base is Hyderabad, India and LSK Global’s headquarters are in Seoul, Korea. Both are active in the US and various European markets, while MakroCare also has a presence in Western Europe.
The alliance agreement enables the two companies to offer a broad spread of services to pharmaceutical, biotechnology and medical device companies in key Asian territories, MakroCare said.
LSK has been providing Phase I to III clinical trial services to domestic and global clients since March 2000. Previous international partnerships have involved US-based CRO PRA International, MDS Pharma Services in Canada, China’s Tigermed Consulting and Japanese CRO Mediscience Planning.
Set up in 1996, MakroCare’s portfolio of services spans consulting, clinical research support, site management, informatics, commercial services such as brand management and regulatory planning, and business/knowledge process outsourcing.
Among the company’s existing partners are Qualitix (clinical operations in Taiwan/China), ADDS (Advanced Drug Development Services – drug safety and clinical monitoring in Europe) and Omnicom (electronic data capture).
